• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Weekly, January 09, 2017

The CenterWatch Weekly, January 09, 2017

January 9, 2017
CenterWatch Staff

Draper, Pfizer partner using organ-on-a-chip technology

Biomedical engineering company Draper has announced a partnership with Pfizer. The goal of the collabora­tion is to use Draper’s Microphysiological Systems (MPS) technology to streamline the preclinical phase of testing new medications. The technology is colloquially known as “organ-on-a-chip.” By using biomedical engineering, Draper aspires to improve the quality of new medica­tions and provide better data in a more cost-effective manner, accelerating the research process for new treatments (e.g., drugs, de­vices, cell therapy). By combining in vitro and in vivo testing, the technology can eliminate some of the hurdles of preclinical testing and help to predict clinical outcomes. It can also measure function more quickly, accurately and cheaply than in traditional models.

2017 begins on a positive note with R&D expansions

The New Year began with a series of expansions. Irvine, California-based drug and supplement maker ChromaDex announced that it will open a new research and devel­opment facility in Boulder, Colorado. Tokyo-based drug maker Eisai and Keio University announced that they will establish a lab as part of a new joint venture. In addition, Crown Bioscience of Santa Clara, California, has announced it is investing $1 million in a new research and development center focused on cardio­vascular and metabolic diseases.

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing